Ignore everything but median progression free surv
Post# of 154141
(Total Views: 894)
Posted On: 02/28/2022 11:02:40 AM
Re: USS JOHNSTON #119286
Ignore everything but median progression free survival and median overall survival as CTMedic said we don't know the basis for any other numbers so those two are the only solid numbers we have.
We still don't know what the mOS is. The mPFS was 29% better than Trodelvy. If the same occurs in mOS then that's 15.6 months mOS.
What confounds things a bit is we don't know what the spread on dosing was. They list 1-51 doses per patient given. But the 51 doses was the length of time from trial start until the data was taken. Were patients still treated with leronlimab after the end of the trials and studies?
With those surviving at 12.1 months I would suspect they were responding very well to the drug and would continue to do so. If Cytodyn has continued dosing in those patients median survival may be past 15.6 months. We also know our longest survival (not in BTD results) extends over two years.
We still don't know what the mOS is. The mPFS was 29% better than Trodelvy. If the same occurs in mOS then that's 15.6 months mOS.
What confounds things a bit is we don't know what the spread on dosing was. They list 1-51 doses per patient given. But the 51 doses was the length of time from trial start until the data was taken. Were patients still treated with leronlimab after the end of the trials and studies?
With those surviving at 12.1 months I would suspect they were responding very well to the drug and would continue to do so. If Cytodyn has continued dosing in those patients median survival may be past 15.6 months. We also know our longest survival (not in BTD results) extends over two years.
Quote:
The median overall survival (mOS) for patients that received higher doses (≥ 525 mg) of leronlimab plus chemotherapy was 12+ months (95% CI, 5.5 – 12+ months), which is superior to SOC chemotherapy (6.6 months) or Sacituzumab Govitecan (SG) (11.8 months), an antibody drug conjugate that received accelerated approval by the FDA in 2020 and regular approval in 2021 for the treatment of patients with unresectable locally advanced or mTNBC who have received ≥ 2 prior systemic therapies. Previously SG received fast track and breakthrough therapy designations. 12% patients in the SG Phase III trial had brain metastasis.
The mOS for patients that received leronlimab plus carboplatin was 12+ months (95% CI, 5.4 – 12+ months). There were 13 mTNBC patients in that group.
The median progression-free survival (mPFS) for patients that received higher doses (≥ 525 mg) of leronlimab plus chemotherapy was 6.2 months (95% CI, 2.6 – 7.5 months), which is significantly longer compared to SOC chemotherapy (2.3 months) or SG (4.8 months).
(16)
(0)